These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 812888)
1. Human platelet-initiated formation and uptake of the C5-9 complex of human complement. Zimmerman TS; Kolb WP J Clin Invest; 1976 Jan; 57(1):203-11. PubMed ID: 812888 [TBL] [Abstract][Full Text] [Related]
2. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex. Miyama A; Kato T; Horai S; Yokoo J; Kashiba S Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074 [TBL] [Abstract][Full Text] [Related]
3. Human peritoneal macrophages. Production in vitro of the active terminal complement components C5 to C9 and a functional alternative pathway of complement. Brief report. Hetland G; Bungum L APMIS; 1988 Jan; 96(1):89-92. PubMed ID: 3345254 [TBL] [Abstract][Full Text] [Related]
4. Secretion of the terminal complement proteins, C5-C9, by human platelets. Houle JJ; Leddy JP; Rosenfeld SI Clin Immunol Immunopathol; 1989 Mar; 50(3):385-93. PubMed ID: 2917425 [TBL] [Abstract][Full Text] [Related]
5. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b. Rosenfeld SI; Jenkins DE; Leddy JP J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820 [TBL] [Abstract][Full Text] [Related]
6. Mechanism of complement-mediated activation of human blood platelets in vitro: comparison of normal and paroxysmal nocturnal hemoglobinuria platelets. Dixon RH; Rosse WF J Clin Invest; 1977 Feb; 59(2):360-8. PubMed ID: 833281 [TBL] [Abstract][Full Text] [Related]
7. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage. Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297 [TBL] [Abstract][Full Text] [Related]
8. Complement lysis of human erythrocytes. II. A unique interaction of human C8 and C9 with paroxysmal nocturnal hemoglobinuria erythrocytes. Packman CH; Rosenfeld SI; Jenkins DE; Leddy JP J Immunol; 1980 Jun; 124(6):2818-23. PubMed ID: 7189536 [No Abstract] [Full Text] [Related]
9. Hereditary C5 deficiency in man. III. Studies of hemostasis and platelet responses to zymosan. Breckenridge RT; Rosenfeld SI; Graff KS; Leddy JP J Immunol; 1977 Jan; 118(1):12-6. PubMed ID: 830743 [TBL] [Abstract][Full Text] [Related]
10. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9. Packman CH; Rosenfeld SI; Jenkins DE; Thiem PA; Leddy JP J Clin Invest; 1979 Aug; 64(2):428-33. PubMed ID: 457861 [TBL] [Abstract][Full Text] [Related]
11. Complement lysis of human erythrocytes. III. Differing effectiveness of human and guinea pig C9 on normal and paroxysmal nocturnal hemoglobinuria cells. Rosenfeld SI; Packman CH; Jenkins DE; Countryman JK; Leddy JP J Immunol; 1980 Nov; 125(5):2063-8. PubMed ID: 6776186 [No Abstract] [Full Text] [Related]
12. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a. Hammer CH; Hänsch G; Gresham HD; Shin ML J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934 [TBL] [Abstract][Full Text] [Related]
13. Alternate complement pathway induction of aggregation and release of 5-hydroxytryptamine and adenosine diphosphate by rabbit platelets. Marney SR; Colley DG; Des Prez RM J Immunol; 1975 Feb; 114(2 Pt 1):696-703. PubMed ID: 804512 [TBL] [Abstract][Full Text] [Related]
14. Terminal complement components play a role in the expression of C5a. Gresham HD; Renfer L; Hammer CH; Frank MM J Immunol; 1987 Feb; 138(3):838-41. PubMed ID: 3805718 [TBL] [Abstract][Full Text] [Related]
17. A novel mutation in the complement regulator clusterin in recurrent hemolytic uremic syndrome. Ståhl AL; Kristoffersson A; Olin AI; Olsson ML; Roodhooft AM; Proesmans W; Karpman D Mol Immunol; 2009 Jul; 46(11-12):2236-43. PubMed ID: 19446882 [TBL] [Abstract][Full Text] [Related]
18. Activation of therminal components of human complement by a trypsin-activated complex of human factor B and cobra venom factor. Miyama A; Kato T; Minoda I; Ueda T; Kashiba S Jpn J Microbiol; 1976 Dec; 20(6):507-16. PubMed ID: 1035353 [TBL] [Abstract][Full Text] [Related]
19. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. II. Physico-chemical characterization of the activated complex. Miyama A; Kato T; Yokoo J; Kashiba S Biken J; 1975 Dec; 18(4):205-14. PubMed ID: 1218075 [TBL] [Abstract][Full Text] [Related]
20. Complement-mediated killing of the Lyme disease spirochete Borrelia burgdorferi. Role of antibody in formation of an effective membrane attack complex. Kochi SK; Johnson RC; Dalmasso AP J Immunol; 1991 Jun; 146(11):3964-70. PubMed ID: 2033266 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]